ICCC
ImmuCell Corporation NASDAQ Listed May 5, 1987$9.60
-2.04%
vs $9.80
Mkt Cap $86.8M
52w Low $4.52
67.0% of range
52w High $12.10
50d MA $10.26
200d MA $8.44
P/E (TTM)
113.5x
EV/EBITDA
25.5x
P/B
3.2x
Debt/Equity
0.5x
ROE
-3.8%
P/FCF
70.7x
RSI (14)
41.80
ATR (14)
$0.28
Beta
0.31
50d MA
$10.26
200d MA
$8.44
Avg Volume
17.4K
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
56 Evergreen Drive · Portland, ME 04103 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | AMC | 0.05 | 0.20 | +300.0% | 10.90 | -1.7% | -7.8% | -3.5% | +0.6% | +3.8% | -0.4% | — |
| May 14, 2026 | AMC | 0.05 | 0.21 | +320.0% | 8.26 | +1.7% | +8.0% | +11.1% | +2.9% | -3.1% | +1.3% | — |
| Mar 4, 2026 | AMC | -0.01 | -0.31 | -3000.0% | 6.46 | -0.6% | -1.7% | +3.9% | -1.8% | +2.3% | +0.3% | — |
| Nov 13, 2025 | AMC | — | -0.02 | — | 6.05 | -8.3% | -10.7% | -9.1% | -7.1% | +3.9% | -3.0% | — |
| Aug 14, 2025 | AMC | — | 0.06 | — | 6.72 | +0.6% | -9.2% | +0.2% | -3.4% | +2.4% | -1.0% | — |
| May 14, 2025 | AMC | — | 0.16 | — | 4.91 | +13.0% | +7.9% | -0.6% | +4.0% | +1.1% | +10.8% | — |
| Feb 25, 2025 | AMC | — | 0.06 | — | 5.10 | +2.9% | +7.5% | -2.4% | -1.3% | -2.3% | +0.8% | — |
| Nov 13, 2024 | AMC | — | -0.09 | — | 3.53 | -0.8% | +2.0% | +0.3% | -1.9% | +1.7% | +0.0% | — |
| Aug 13, 2024 | AMC | — | -0.20 | — | 3.76 | +1.1% | -4.3% | +2.5% | -0.5% | +0.8% | -1.1% | — |
| May 14, 2024 | AMC | — | -0.06 | — | 5.48 | -3.6% | -10.9% | -1.6% | +0.2% | -1.5% | +0.4% | — |
| Feb 27, 2024 | AMC | — | -0.15 | — | 5.14 | +1.4% | +1.6% | +1.1% | +0.0% | +3.4% | -2.9% | — |
| Nov 13, 2023 | AMC | — | -0.12 | — | 5.20 | +2.9% | +1.9% | -5.3% | -6.4% | +1.3% | -3.1% | — |
| Aug 10, 2023 | AMC | — | -0.18 | — | 5.02 | +1.6% | -0.4% | +0.4% | -0.8% | -0.4% | +0.8% | — |
| May 11, 2023 | AMC | — | -0.30 | — | 4.96 | -4.2% | -6.5% | +7.1% | +4.8% | -1.3% | -5.3% | — |
No analyst ratings available.
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | te Boekhorst Paul Francis OlivierDir/Off | President and CEO | Buy | 8,000 | $9.49 | $76K | 17,785 | +1.33% | +1.23% |
8-K · 2.02
!! High
ImmuCell Corporation -- 8-K 2.02: Earnings Results
Jul 9
8-K
ImmuCell Corporation -- 8-K Filing
Jun 17
8-K · 7.01
! Medium
ImmuCell Corporation -- 8-K 7.01: Regulation FD Disclosure
Jun 10
8-K · 2.02
!! High
ImmuCell Corporation -- 8-K 2.02: Earnings Results
May 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive effective April 15, 2026 signals potential leadership uncertainty; investors should monitor whether the replacement demonstrates strategic continuity or signals broader organizational concerns affecting these companies' performance.
Apr 14
8-K
Unknown — 8-K Filing
ICCC issued a press release on April 8, 2026, signaling potential material news that investors should monitor through the full filing for earnings updates, strategic announcements, or operational developments affecting stock valuation.
Apr 8
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K
Immucell Corp -- 8-K Filing
ImmuCell Corporation reported 2025 net operating income of $1.6 million, a $3.3 million improvement year-over-year, signaling strengthened operational performance and profitability turnaround.
Mar 4
8-K · 5.02
!!! Very High
Immucell Corp -- 8-K 5.02: Executive Change
The departure of an executive at Immucell raises concerns about management stability and internal operations, potentially signaling underlying issues that could impact the company's strategic direction and investor confidence.
Feb 9
8-K · 5.02
!!! Very High
Immucell Corp -- 8-K 5.02: Executive Change
Immucell Corp established clawback provisions for executive annual cash bonuses, allowing retroactive recovery if required by policy or regulations, affecting future executive compensation structures and governance practices.
Feb 2
Institutional (13F) — Top 18
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 268,130 | $3M | Added | Jun 2026 |
| 2 | Renaissance Technologies Llc | 171,089 | $2M | Added | Jun 2026 |
| 3 | Morgan Stanley | 249,432 | $2M | Added | Dec 2025 |
| 4 | Cresset Asset Management, Llc | 132,001 | $854K | — | Sep 2025 |
| 5 | Citadel Advisors Llc | 81,006 | $814K | Added | Jun 2026 |
| 6 | Steadtrust Llc | 45,370 | $456K | Reduced | Jun 2026 |
| 7 | Mesirow Financial Investment Management, Inc. | 42,481 | $427K | — | Jun 2026 |
| 8 | Strategic Financial Services, Inc. | 37,000 | $372K | — | Jun 2026 |
| 9 | Northern Trust Corp | 41,618 | $263K | Added | Mar 2026 |
| 10 | Blackrock, Inc. | 22,860 | $230K | New | Jun 2026 |
| 11 | Quadrature Capital Ltd | 15,415 | $155K | New | Jun 2026 |
| 12 | Militia Capital Management Llc | 10,000 | $100K | New | Jun 2026 |
| 13 | Bailard, Inc. | 10,102 | $64K | New | Mar 2026 |
| 14 | Hm Payson & Co | 4,000 | $40K | — | Jun 2026 |
| 15 | Ubs Group Ag | 1,113 | $7K | Reduced | Mar 2026 |
| 16 | Capital Advisors, Ltd. Llc | 98 | $1K | — | Mar 2026 |
| 17 | Caitong International Asset Management Co., Ltd | 5 | $50 | New | Jun 2026 |
| 18 | Wells Fargo & Company/mn | 1 | $4 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 18
All ↗
Valuation
Market Cap
$86.8M
Enterprise Value
$90.3M
P/E (TTM)
113.48x
Forward P/E
—
PEG Ratio
0.99x
P/B
3.20x
P/S
2.82x
P/FCF
70.74x
EV/EBITDA
25.54x
Shares Out
9.0M
Financials (TTM)
Revenue
$30.7M
Net Income
$787K
EBITDA
$3.5M
Free Cash Flow
$1.2M
Op Cash Flow
$2.5M
EPS Basic
$-0.12
EPS Diluted
$0.08
EPS Forward
$-0.24
Gross Margin
40.3%
Op Margin
12.6%
Net Margin
2.6%
Balance Sheet
Total Assets
$42.5M
Total Liab.
$15.5M
Total Equity
$27.1M
Cash
$3.8M
LT Debt
$7.5M
Book Value/Sh
$3.00
Debt/Equity
0.49x
Current Ratio
4.26
Quick Ratio
1.93
Returns & Growth
ROE
-3.8%
ROA
-2.5%
ROIC
4.1%
Rev Growth YoY
+4.3%
EPS Growth YoY
+53.8%
Price Returns
2W
-3.8%
1M
-4.0%
3M
-6.7%
6M
+49.1%
12M
+46.6%
Technicals
52W High
$12.10
52W Low
$4.52
50d MA
$10.26
200d MA
$8.44
RSI (14)
41.80
ATR (14)
$0.28
Beta
0.31
Avg Volume
17K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 2:48pm
· Source: financialmodelingprep.com